I am incredibly grateful to receive the Teaching Star Commendation from Albert Einstein College of Medicine - Official/Montefiore Health System. Thank you Andrew Gutwein MD, Jacobi Internal Medicine Chiefs and our house staff for your unwavering support and invaluable mentorship through residency. It is an honor to learn from you all.

So honored to be inducted into the Einstein Chapter of the #AOA Honor Medical Society! Thank you Albert Einstein College of Medicine - Official for this honor 🙏🏼 Endlessly grateful for my Jacobi family, program leadership and PD for their support and nomination Andrew Gutwein MD Jacobi Internal Medicine Chiefs 🥰

To more milestones together 👩🏻‍🤝‍👨🏼 - Internal Medicine Residency Graduation 2023 👩🏻‍⚕️👨🏼‍⚕️

Long overdue introduction but we’re so excited for our new role as chiefs and looking forward to what this year has in hold for us with our brilliant residents 🫶🏻 #JacobiStrong #Chiefs2023

So honored and thrilled to be joining Columbia for my hematology/oncology training 🩸 Herbert Irving Comprehensive Cancer Center Forever thankful for my mentors and program for their endless support 🙏🏼 Can’t believe we get to share yet another journey working alongside each other 👩🏻‍🤝‍👨🏼❤️ Abdul-Hamid Bazarbachi, MD

Timing and Outcomes of 2nd line therapy in the era of frontline Dara-VCd in AL #Amyloidosis-Our experience CAMP@CUIMC to be presented at #EHA24 by Abdul-Hamid Bazarbachi, MD! Suzanne Lentzsch, MD, PhD tinyurl.com/mrkvaxjf

If you’re attending #EHA24, please visit ⁦IACH⁩ booth to enjoy a tasty ice-cream, while discovering the wide range of the IACH educational activities. Our vision of «Hematology Without Borders» has become a reality thanks to the incredible support of all stakeholders.

Single-cell genomics-based immune and disease monitoring in blood malignancies just published in “Clin Hematol Int”, the official open access peer-reviewed journal of ⁦IACH⁩ - this is very a timely review in light of the advances at #EHA24 chi.scholasticahq.com/article/117961

Optimal second line treatment for AL Amyloidosis after Daratumuab treatment 👉presented by super-fellow Abdul-Hamid Bazarbachi, MD and his super-mentor Raj Chakraborty at #EHA24 Herbert Irving Comprehensive Cancer Center #mmsm

🚶🏻‍♂️🚶🏾🚶🏻‍♀️Lining up to take a picture at IACH Photo Booth #EHA24 We welcome you to visit us at the IACH booth M11 European Hematology Association Mohamad Mohty

The crowd at ⁦IACH⁩ booth during #EHA24 THANK YOU all for your wonderful support to our «Hematology Without Borders» vision.

An old, cheap, and globally accessible drug is able to double the MRD-negativity rate at 10^-6!! Also, kudos to investigators for testing Bortezomib in a once weekly subcutaneous schedule! #EHA24 #mmsm

In BENEFIT trial, time to VGPR significantly shorter with Isa-VRD vs VRD! Important consideration in patients with myeloma cast nephropathy, where time is nephron! Bortezomib should remain an important component of treatment in those patients even in the CD38 era! #EHA24 #mmsm

CASSIOPEIA 7-yr update: Does Dara maintenace add benefit pts who receive Dara-based induction? New data suggest a marginal benefit, but note heavy censoring beyond 5 yrs! Will this hold up in DR vs R? My take: I remain skeptical of Dara in Mx pending GMMG-HD7/DRAMMATIC! #EHA24

Always nice to see long-term follow up results! Dr. Moreau pointed out that >80% of patients in Dara-VTD arm of CASSIOPEIA are alive at 8 years despite half of them getting no maintenace! Exciting prospects indeed for limited duration therapy in #MultipleMyeloma! #EHA24

Led by med student Darshi Shah and in collaboration with Fabio Efficace Fondazione GIMEMA, we present the most comprehensive landscape of PROs in #MultipleMyeloma RCTs at #EHA24! ▪️ PRO domain most sensitive to change: GHS/QoL ▪️ Most common experimental arms associated with improved

The myeloma ⁦Herbert Irving Comprehensive Cancer Center⁩ team celebrates farewell to a great #EHA2024 meeting ⁦Raj Chakraborty⁩ ⁦Abdul-Hamid Bazarbachi, MD⁩

🚨 Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid leukemia in first complete remission: data from the EBMT. Worse outcomes with consolidation with alloSCT in CR1 compared to ASCT. Mohamad Mohty

Our study on the landscape of 2nd line therapies in AL #Amyloidosis in 100 consecutive newly diagnosed patients treated with Dara-VCd at CAMP@CUIMC (led by Abdul-Hamid Bazarbachi, MD)! 3 key findings: ✅~1/3rd required 2nd LoT (median f/u ~2 years) ✅Best outcomes seen with

Great catching up with my amazing friends from Jacobi Residency at the #SOHO2024. Always learning and growing together. Society of Hematologic Oncology (SOHO) Roha Saeed Memon, MD Abdul-Hamid Bazarbachi, MD Karun Neupane, MD Andrew Gutwein MD MD Anderson Cancer Center Jacobi Internal Medicine Chiefs